Premium
P2‐345: DO THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE ESTIMATES FOR CLINICAL OUTCOME ASSESSMENTS FOR ALZHEIMER'S DISEASE DIFFER BY DISEASE SEVERITY?
Author(s) -
Andrews Jeffrey Scott,
Desai Urvi,
Kirson Noam Y.,
Zichlin Miriam,
Ball Daniel,
Matthews Brandy R.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1035
Subject(s) - clinical dementia rating , minimal clinically important difference , medicine , dementia , cohort , alzheimer's disease , disease , cognition , cognitive decline , clinical endpoint , gerontology , physical therapy , clinical trial , psychiatry , randomized controlled trial
(Animals) verbal fluency scores were stable in half the patients. Phonemic verbal fluency (Letters) was stable in 3 of 5 patients. All patients remained living in the community. Conclusions: We have for the first time demonstrated stabilization of cognition function in MCI and Dementia for up to 15 years of therapy. Combined therapy is a viable treatment option for medically ill people with dementia until new effective medications become available.